Stockreport

ArriVent BioPharma Reports Full Year 2025 Financial Results [Yahoo! Finance]

ArriVent BioPharma, Inc.  (AVBP) 
PDF ArriVent BioPharma, Inc. Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 Global pivotal Ph [Read more]